Table 1 Patients characteristics
Variables | |
|---|---|
Number of patients (n) | 43 |
Age (median [range]) | 61 (35–78) |
Gender (# male [%]) | 19 (44.2%) |
Stage (n [%]) | IIIb: 4 (9.3%); IV: 39 (90.7%) |
Demonstrable EGFR mutations (n [%]) | 5 (11.6%) |
Disease stabilization at 12 weeks (n [%]) | 23 (53.5%) |
Tumor shrinkage at 12 weeks (median [IQR]), in % of tumor size at baseline | 15.8% (−2.5 to 26.2%) |
Median overall survival (95% CI), in months | 11.1 (10.1–17.9) |
Median time-to-progression under BE (95% CI), in months | 4.0 (2.8–6.0) |
Median time-to-progression under CT (95% CI), in months | 2.6 (1.7–5.7) |